Evaluation of cardiac uptake during a PET examination 18F Flutematamol (Vizamyl®) in cardiac damage amyloid.
Phase 1
- Conditions
- Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2013-003911-23-FR
- Lead Sponsor
- CHU Toulouse
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Assessing myocardial uptake of 18F-flutemetamol (Vizamyl®) in patients with cardiac amyloid reached.;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method